![](/images/graphics-bg.png)
Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study
المؤلفون المشاركون
Wen, Maoyao
Yang, Li
Fan, Xiaoli
Zhu, Yongjun
Men, Ruoting
Shen, Yi
Lu, Changli
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-08-02
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Aim.
To explore the efficacy and safety of immunosuppressive therapy for the treatment of primary biliary cirrhosis-autoimmune hepatitis (PBC-AIH) overlap syndrome accompanied by decompensated cirrhosis.
Methods.
A cohort study was performed to evaluate the usefulness of immunosuppressive therapy in this unique group.
This cohort study was performed between October 2013 and June 2017 and included 28 biopsy-proven patients diagnosed according to the Paris criteria.
The therapies included ursodeoxycholic acid (UDCA) alone (N=14) or in combination with immunosuppression (IS) therapy (N=14).
The primary endpoints were biochemical remission, liver-related adverse events, transplant-free survival, and drug side-effects.
Results.
The frequency of biochemical remission for the AIH features was significantly higher in the UDCA+IS group than in the UDCA-only group (60.0 versus 9.1%, P=0.024) after 12 months of therapy but not after 3 and 6 months (28.6 versus 0%, P=0.165; 35.7 versus 7.1%, P=0.098).
The rates of liver-related adverse events were lower in the combined group (2/14 versus 9/14, P=0.018).
The Kaplan-Meier estimate showed that the transplant-free survival was distinct between the two groups (P=0.019).
In the UDCA+IS group, mild and transient leukopenia occurred in two patients receiving azathioprine (AZA), and an infection was observed in one patient receiving mycophenolate mofetil (MMF).
Conclusions.
PBC-AIH patients with decompensated cirrhosis receiving a combination of UDCA and immunosuppressors presented with higher biochemical remission rates and experienced fewer liver-related adverse events, implying that the combined treatment might be a better therapeutic option for strictly defined decompensated PBC-AIH overlap syndrome.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Fan, Xiaoli& Zhu, Yongjun& Men, Ruoting& Wen, Maoyao& Shen, Yi& Lu, Changli…[et al.]. 2018. Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1130882
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Fan, Xiaoli…[et al.]. Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1130882
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Fan, Xiaoli& Zhu, Yongjun& Men, Ruoting& Wen, Maoyao& Shen, Yi& Lu, Changli…[et al.]. Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1130882
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130882
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)